MARKET

ACHV

ACHV

Achieve Life Sciences Inc
NASDAQ
2.640
-0.110
-4.00%
After Hours: 2.700 +0.06 +2.27% 19:38 07/15 EDT
OPEN
2.850
PREV CLOSE
2.750
HIGH
2.850
LOW
2.460
VOLUME
2.55M
TURNOVER
--
52 WEEK HIGH
5.31
52 WEEK LOW
1.840
MARKET CAP
131.17M
P/E (TTM)
-1.9724
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACHV last week (0707-0711)?
Weekly Report · 1d ago
Raymond James Predicts Up to ~760% Surge for These 2 ‘Strong Buy’ Stocks
TipRanks · 3d ago
Achieve Life Sciences Completes Key Study on Cytisinicline for Renal Impairment
TipRanks · 4d ago
Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation
Seeking Alpha · 07/07 17:55
Achieve Life Sciences Inc. Unveils Corporate Presentation on Innovative Nicotine Dependence Treatment and Market Strategy
Reuters · 07/07 13:37
Weekly Report: what happened at ACHV last week (0630-0704)?
Weekly Report · 07/07 09:31
Achieve Life Sciences (ACHV) Receives a Buy from Raymond James
TipRanks · 07/01 13:15
ACHIEVE LIFE SCIENCES ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK AND PARTIAL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SECURITIES
Reuters · 06/30 23:52
More
About ACHV
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.

Webull offers Achieve Life Sciences Inc stock information, including NASDAQ: ACHV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACHV stock methods without spending real money on the virtual paper trading platform.